As a world leader in pharmaceutical services, Almac delivers bespoke crystallisation development work programs for small molecules and peptides designed to provide a robust, scaleable, and transferrable crystallisation procedure to help accelerate clinical development and minimise risk in any downstream activities by eliminating batch-to-batch variability. The goals of typical studies include:

• Impurity rejection / purge studies
• Kinetics of nucleation and growth
• Polymorphic form control
• Maximising yield
• Morphology engineering studies
• Particle size control
• Bulk density and powder flow improvement
• Milling and micronisation studies
• Isolation and drying processes
• Control over residual solvent
• Seeding protocol

Read the full article below to learn more.